The publication detail shows the title, authors (with indicators showing other profiled authors), information on the publishing organization, abstract and a link to the article in PubMed. This abstract is what is used to create the fingerprint of the publication. If any grants are referenced by the publication, they will be listed here as well.
Equivalent success of simultaneous pancreas kidney and solitary pancreas transplantation. A prospective trial of tacrolimus immunosuppression with percutaneous biopsy.
S T Bartlett; E J Schweitzer; L B Johnson; P C Kuo; J C Papadimitriou; C B Drachenberg; D K Klassen; E W Hoehn-Saric; M R Weir; A L Imbembo (Profiled Authors: Cinthia Drachenberg; David K Klassen; John C Papadimitriou; Eugene J Schweitzer; Matthew R Weir; Stephen T Bartlett)
Department of Surgery, University of Maryland School of Medicine, Baltimore, USA.
Annals of surgery 1996;224(4):440-9; discussion 449-52.
OBJECTIVE: This study was designed to evaluate the results of solitary pancreas transplantation in a protocol that uses the new immunosuppressant tacrolimus (FK) and liberally applies ultrasound-guided percutaneous pancreas biopsy to diagnose rejection. SUMMARY BACKGROUND DATA: Pancreas graft survival in patients who simultaneously receive a kidney transplant (SPK) historically has been 75% to 90% at 1 year, approaching that of cadaveric kidney transplantations. In sharp contrast, graft survival rates in patients who receive a pancreas atone (PA) have remained static over the past decade, with approximately 50% functional at 1 year. It was hypothesized that the results of PA transplantations would improve with newer maintenance immunosuppressants and biopsy techniques. METHODS: Twenty-seven PA recipients prospectively were treated with FK-based immunosuppression (PA-FK). Percutaneous biopsy was performed for hyperamylasemia, hyperlipasemia, hypoamylasuria, or unexplained fever. One year pancreas graft survival in these patients was compared to 15 cyclosporine treated PA cases (PA-CsA) and 113 SPK recipients. RESULTS: The 1-year pancreas graft survival rate of 90.1% in technically successful PA-FK patients was significantly better than the 53.4% rate in PA-CsA recipients (p = 0.002) and no different than the 87.4% rate in SPK recipients. The only graft lost to acute rejection in the PA-FK group was because of acknowledged patient noncompliance. Percutaneous biopsy substantially improved the diagnostic certainty in cases of suspected rejection and was associated with a low complication rate (3/178 = 1.5%). CONCLUSIONS: Modern immunosuppression and biopsy techniques have improved the success of solitary pancreas transplantations to the point where outcome is now equivalent to that of SPKs.
This section shows information related to the publication - computed using the fingerprint of the publication - including related publications, related experts and related grants with fingerprints representing significant amounts of overlap between their fingerprint and this publication. The red dots indicate whether those experts or terms appear within the publication, thereby showing potential and actual connections.
Ghazal Vessal; Anne M Wiland; Benjamin Philosophe; Jeffrey C Fink; Matthew R Weir; David K KlassenClinical transplantation 2007;21(4):491-7.
J A Walker; D K Klassen; F J Hooper; E W Hoehn-Saric; E J Schweitzer; L B Johnson; S T Bartlett; M R WeirTransplantation 1996;62(4):539-43.
V T Armenti; C H McGrory; J Cater; J S Radomski; B E Jarrell; M J MoritzTransplantation proceedings 1997;29(1-2):669-70.
Appears in this Publication
Author of this Publication